CT 32228
Based on 1 Customer Validation
CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β (LPAAT-β). CT 32228 inhibits tumor cell growth. CT 32228 exhibits IC50 values of around 0.1-0.8 μM in various leukemia cell lines. CT 32228 induces caspase activation in DHL-4 and Ramos cells. CT 32228 induces apoptosis when combined with Rituximab (HY-P9913). CT 32228 results in a 50% xenograft growth delay in vivo. CT 32228 can be studied in research on acute leukemia.
For research use only. We do not sell to patients.
- Purity: 95.27%
- CAS No.: 521064-34-6
- Formula: C16H13BrClN5
- Molecular Weight:390.66
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| AN3-CA | IC50 |
0.037 μM
Compound: CT-32228
|
Cytotoxicity against human AN3-CA cells assessed as cell growth inhibition
Cytotoxicity against human AN3-CA cells assessed as cell growth inhibition
|
[PMID: 35981459] |
Chemical Information
-
CAS No. 521064-34-6
-
Appearance Solid
-
Molecular Weight 390.66
-
Formula C16H13BrClN5
-
SMILES
ClC1=CC(C2=NC(NC3=CC=C(C=C3)Br)=NC(N)=N2)=C(C)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
References
[1]. Douvas MG, et al., Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leuk Res. 2006 Aug;30(8):1027-36. [Content Brief]
[2]. Pagel JM, et al., Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Jul 1;11(13):4857-66. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)